Restatement of Previously Reported Condensed Consolidated Financial Statements | Note 2. As previously disclosed on Form 8-K filed on November 16, 2021, the Company determined that the Company’s previously issued financial statements for the periods ended March 31, 2021 and June 30, 2021 should no longer be relied upon due to errors in such condensed consolidated financial statements related to revenue reported by Timios that provides title and agency services. The preparation of the Company’s condensed consolidated financial statements identified additional transactions and accounting practices not in accordance with U.S. GAAP. The following errors were identified as part of the restatement: A. The Company determined that it did not present Timios title and agency services revenue and the related cost of revenue in accordance with US GAAP on the condensed consolidated statement of operations, as premiums from title insurance policies written by independent agencies were presented on a gross basis and did not properly present revenue and cost of revenue net of commission costs. B. The Company discovered that it did not properly account for its investment in Technology Metals Market Limited (“TM2”) in accordance with the equity method of accounting.In addition, the Company determined that it incorrectly presented equity income (loss) on its equity method investments as a component of interest and other income (expense) on the condensed consolidated statements of operations rather than as a separate financial statement caption below income taxes. C. The Company discovered certain errors in determining the estimated fair value of acquired intangible assets in its purchase price allocation for its acquisitions. D. The Company determined that the errors in determining the estimated fair value of net assets acquired in its acquisitions resulted in an additional reduction to the Company’s deferred tax liabilities. E. The Company determined that it did not properly recognize income tax expense (benefit) for certain acquired entities subsequent to their respective acquisitions during the six months ended June 30, 2021. The following reflects the restatement adjustments recorded in connection with the Company’s restatement of its condensed consolidated financial statements: Consolidated Balance Sheet June 30, 2021 As Previously Reported Adjustment As Restated Notes Assets Cash and cash equivalents $ 395,642 $ — $ 395,642 Accounts receivable, net 4,039 — 4,039 Available for sale security 15,360 — 15,360 Inventory 3,573 — 3,573 Prepaid expenses 12,069 — 12,069 Amount due from related parties 294 — 294 Other current assets 1,291 — 1,291 Current assets held for sale 7,068 — 7,068 Total current assets 439,336 — 439,336 Property and equipment, net 1,058 — 1,058 Intangible assets, net 107,352 (17,400) 89,952 C Goodwill 104,193 12,879 117,072 C Long-term investments 32,457 (281) 32,176 B Operating lease – right of use assets 12,423 (6,774) 5,649 * Other noncurrent assets 1,232 6774 8,006 * Total assets $ 698,051 $ (4,802) $ 693,249 Liabilities and Stockholders’ Equity Accounts payable $ 8,456 $ — $ 8,456 Deferred revenue 1,707 — 1,707 Accrued salaries 5,710 — 5,710 Due to related party 1,111 — 1,111 Other current liabilities 8,210 47 8,257 *, E Current portion of lease liabilities 1,940 (322) 1,618 * Current contingent consideration 11,712 — 11,712 Note payable 1,228 — 1,228 Note payable – related party — — — Convertible promissory note to third parties 81,224 — 81,224 Asset retirement obligations 4,653 — 4,653 Total current liabilities 125,971 (275) 125,696 Asset retirement obligations — — — Deferred tax liabilities 2,971 (1,215) 1,756 C, D, E Operating lease liability – long term 10,530 (6,577) 3,953 * Non-current contingent consideration 4,637 — 4,637 Other long-term liabilities 1,284 6,577 7,861 * Total liabilities 145,393 (1,490) 143,903 Convertible redeemable preferred stock and Redeemable non-controlling interest: Series A Preferred stock 1,262 — 1,262 Redeemable non-controlling interest 7,716 — 7,716 Stockholders’ equity Preferred stock, $0.0001 par value — — — Common stock, $0.0001 par value 466 — 466 Additional paid-in capital 894,285 — 894,285 Accumulated deficit (357,245) (3,312) (360,557) Accumulated other comprehensive income 730 — 730 Total IDEX stockholders’ equity 538,236 (3,312) 534,294 Noncontrolling interests 5,444 — 5,444 Total stockholders’ equity 543,680 (3,312) 540,368 Total liabilities and stockholders’ equity $ 698,051 $ (4,802) $ 693,249 * Represents revision for immaterial error correction – see Note 1 Condensed Consolidated State of Operations for three months ended June 30, 2021 As Restatement As Reported ** Adjustments Restated Notes Revenue - sales of products $ 7,410 $ — $ 7,410 Revenue - sales of services 25,807 (2,371) 23,436 A Total Revenue 33,217 (2,371) 30,846 Cost of revenue - sales of products 6,591 — 6,591 Cost of revenue - sales of services 17,325 (2,371) 14,954 A Total Cost of revenue 23,916 (2,371) 21,545 Gross Profit 9,301 — 9,301 Operating Expenses Selling, general and administrative 13,076 (154) 12,922 (1) Research and development 235 — 235 Professional fees 7,439 — 7,439 Impairment losses — — — Change -fair value of contingent consideration (2,402) — (2,402) Litigation settlement _ — _ Depreciation and amortization 1,635 — 1,635 Total operating expenses 19,983 (154) 19,829 Loss from operations (10,682) 154 (10,528) Interest and other income (expense): Interest expense, net (563) — (563) Loss on disposal of subsidiaries (1,234) — (1,234) Conversion expense — — — Gain on measurement of investments 2,915 — 2,915 Other income, net 990 (154) 836 (1) Loss before income taxes and non-controlling interest (8,574) — (8,574) Income tax (expense) benefit (1,061) 2,631 1,570 C, D, E Equity in loss of equity method investees (358) (103) (461) B Net loss (9,993) 2,528 (7,465) Deemed dividend related to warrant repricing — — — — Net loss attributable to common shareholders (9,993) 2,528 (7,465) Net loss attributable to non-controlling interest 203 — 203 Net loss attributable to IDEX common shareholders $ (9,790) $ 2,528 $ (7,262) Earnings per share, basic & fully diluted $ (0.02) $ — $ (0.02) Weighted average number of common shares 433,098,279 0 433,098,279 Condensed Consolidated Statement of Operations for Six Months ended June 30, 2021 As Restatement As Reported ** Adjustments Restated Notes Revenue - sales of products $ 11,957 $ — $ 11,957 Revenue - sales of services 53,969 (5,141) 48,828 A Total Revenue 65,926 (5,141) 60,785 Cost of revenue - sales of products 10,945 — 10,945 Cost of revenue - sales of services 34,838 (5,141) 29,697 A Total Cost of revenue 45,783 (5,141) 40,642 Gross Profit 20,143 — 20,143 Operating Expenses Selling, general and administrative 25,081 (308) 24,773 (1) Research and development 245 — 245 Professional fees 12,607 — 12,607 Impairment losses — — — Change -fair value of contingent consideration (1,907) — (1,907) Litigation settlement 5,000 — 5,000 Depreciation and amortization 2,763 — 2,763 Total operating expenses 43,789 (308) 43,481 Loss from operations (23,646) 308 (23,338) Interest and other income (expense): Interest expense, net (980) — (980) Loss on disposal of subsidiaries (1,446) — (1,446) Conversion expense — — — Gain on measurement of investments 2,915 — 2,915 Other income, net 988 (308) 680 (1) Loss before income taxes and non-controlling interest (22,169) — (22,169) Income tax benefit 11,855 (3,030) 8,825 C, .D,E, Equity in loss of equity method investees (417) (281) (698) B Net loss (10,731) (3,311) (14,042) Deemed dividend related to warrant repricing — — — — Net loss attributable to common shareholders (10,731) (3,311) (14,042) Net loss attributable to non-controlling interest 367 — 367 Net loss attributable to IDEX common shareholders $ (10,364) $ (3,311) $ (13,675) Earnings per share, basic & fully diluted $ (0.03) $ — $ (0.03) Weighted average number of common shares 412,230,966 0 412,230,966 ** Reflects the presentation of equity in loss of equity method as a separate financial statement caption below income tax (expense) benefit. (1) Reflects immaterial error correction for the classification of other income. Condensed Consolidated Statement of Comprehensive Loss for the Three Months ended June 30, 2021 As Restatement As Reported Adjustments Restated Notes Net loss $ (9,993) $ 2,528 $ (7,465) Other comprehensive loss, net of tax: Change in fair value of AFS securities (20) (20) Foreign currency translation adjustments (41) — (41) Comprehensive loss (10,054) 2,528 (7,526) Comprehensive loss attributable to non-controlling interest 210 — 210 Comprehensive loss attributable to IDEX $ (9,844) 2,528 $ (7,316) Condensed Consolidated Statement of Comprehensive Loss for the Six Months Ended June 30, 2021 As Restatement As Reported Adjustments Restated Notes Net loss $ (10,731) $ (3,311) $ (14,042) Other comprehensive loss, net of tax: Change in fair value of AFS securities (20) (20) Foreign currency translation adjustments (901) — (901) Comprehensive loss (11,652) (3,311) (14,963) Comprehensive loss attributable to non-controlling interest 763 — 763 Comprehensive loss attributable to IDEX $ (10,889) (3,311) $ (14,200) Condensed Consolidated Statement of Equity for the Six Months Ended June 30, 2021 Common Par Accumulated IDEX Total Stock Value APIC Deficit AOCI Equity NCI Equity Balance - March 31, 2021 (as reported) 419,469,800 $ 419 $ 761,155 $ (347,457) $ 784 $ 414,901 $ 5,770 $ 420,671 Adjustments Equity method investment (178) (178) (178) Income tax effects (5,660) (5,660) (5,660) Balance - March 31, 2021 (as restated) 419,469,800 $ 419 $ 761,155 $ (353,295) $ 784 $ 409,063 $ 5,770 $ 414,833 Balance - June 30, 2021 (as reported) 466,354,487 $ 466 $ 894,285 $ (357,245) $ 730 $ 538,236 $ 5,444 $ 543,680 Adjustments Equity method investment (281) (281) (281) Income tax effects (3,030) (3,030) (3,030) Balance - June 30, 2021 (as restated) 466,354,487 $ 466 $ 894,285 $ (360,556) $ 730 $ 534,925 $ 5,444 $ 540,369 Condensed Consolidated Statement of Cash Flows for the Six Months Ended June 30, 2021 As Restatement As Reported Adjustments Restated Notes Cash flows from operating activities: Net loss $ (10,731) $ (3,311) $ (14,042) B, C, D, E Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 4,047 — 4,047 Depreciation and amortization 2,763 — 2,763 Non-cash interest expense 991 — 991 Allowance for doubtful accounts 340 — 340 Litigation settlement 5,000 (5,000) — (1) Income tax benefit (12,222) (3,030) (9,192) C, D, E Loss on disposal of subsidiaries 1,446 — 1,446 Equity in losses of equity method investees 417 281 698 B Issuance of common stock for professional fees — 1,819 1,819 (1) Gain on extinguishment of liability (777) — (777) Gain on remeasurement of investment (2,915) — (2,915) Impairment losses — — — Settlement of ROU operating lease liabilities — — — Change in fair value of contingent consideration (1,907) — (1,907) Change in assets and liabilities: Accounts receivable 5,503 — 5,503 Inventory 379 — 379 Prepaid expenses and other assets (7,711) (7,711) Accounts payable (60) (60) Deferred revenue (1,497) (1,497) Amount due to related parties 770 770 Accrued expenses, salary and other current liabilities 5,794 3,181 8,975 (1) Net cash used in operating liabilities (10,370) — (10,370) Cash flows from investing activities: Acquisition of property and equipment (603) (603) Disposal of subsidiaries (44) (44) Acquisition of subsidiaries (100,579) (100,579) Investment in long-term investment (26,083) (26,083) Notes receivable — — Investment in debt securities (15,528) (15,528) Net cash used in investing activities (142,837) — (142,837) Cash flows from financing activities Proceeds from issuance of convertible notes 220,000 220,000 Proceeds from exercise of options and warrants 163,046 163,046 Proceeds from noncontrolling interest shareholder — — Borrowings from SBA PPP — — Repayment of amounts due to related parties — — Net cash provided by financing activities 383,046 — 383,046 Effect of exchange rate changes on cash 39 39 Net increase in cash and cash equivalents 229,878 — 229,878 Cash and cash equivalents - beginning of period 165,764 — 165,764 Cash and cash equivalents - end of period $ 395,642 — $ 395,642 (1) |